Q-omics provides the consensus-scored TRIM75P profile across patient tissues and cancer cell-line models. TRIM75P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TRIM75P is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, TRIM75P RNA expression shows 11,300 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where TRIM75P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM75P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM75P survival associations across molecular data types. TRIM75P RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM75P RNA expression–survival associations across cancer types. High TRIM75P expression shows unfavorable associations in KICH, UVM, OV, LUSC and THCA, but favorable associations in READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TRIM75P RNA expression.
This table summarizes TRIM75P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM75P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM75P shows lower tumor expression in LUAD and BRCA and higher tumor expression in KIRC, KICH and LIHC. The KIRC box plot shows higher TRIM75P RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p < 0.001).
This table shows molecular features associated with TRIM75P in patient tissues and cancer cell lines. In patient samples, TRIM75P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
